# Gregory J. Riely

Source: https://onco.cc/people/gregory-riely/  
OnCo record `gregory-riely` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lung cancer doctor who led PHAROS, the trial that brought the encorafenib and binimetinib pair to BRAF V600E-mutant lung cancer.

## Summary

Gregory Riely is a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center. He was first author of the 2023 Journal of Clinical Oncology report of PHAROS, the phase 2 trial of encorafenib plus binimetinib in BRAF V600E-mutant metastatic non-small-cell lung cancer that supported the combination's approval, and has long worked on KRAS-mutant lung cancer and the clinical use of tumour genotyping.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: lung; targeted-therapy; trialist
- Role: Thoracic medical oncologist, Memorial Sloan Kettering Cancer Center
- Specialisms: BRAF-mutant lung cancer; KRAS-mutant lung cancer; Targeted therapy

## Connected records

- cancers: [BRAF V600E-mutant non-small-cell lung cancer](https://onco.cc/cancers/braf-v600e-nsclc/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- key papers: [PHAROS: encorafenib plus binimetinib in BRAF V600E-mutant metastatic non-small-cell lung cancer](https://onco.cc/key-papers/paper-pharos-encorafenib-binimetinib-riely-jco-2023/)

---
JSON: https://onco.cc/api/v1/entities/gregory-riely.json